2-(furan-3-yl)pyrazine | 29460-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(furan-3-yl)pyrazine
• 英文别名: 3-Furanylpyrazine
• CAS: 29460-98-8
• 化学式: C₈H₆N₂O
• 分子量: 146.148
• InChiKey: RQPWPLHJVUKYOR-UHFFFAOYSA-N

物化性质

• 熔点：
  64-66 °C
• 沸点：
  252.7±30.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯吡嗪 、 3-呋喃硼酸 在 palladium diacetate 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate 作用下， 以 仲丁醇 为溶剂， 反应 12.0h， 以96%的产率得到2-(furan-3-yl)pyrazine
  参考文献：
  名称：

  用于钯催化的杂芳基卤化物和杂芳基硼酸和酯的 Suzuki-Miyaura 反应的高效单膦基催化剂

  摘要：

  已经开发了一种高活性和高效的催化剂体系，该体系源自钯预催化剂和单膦配体 1 或 2，用于杂芳基硼酸和酯的 Suzuki-Miyaura 交叉偶联反应。该方法允许以良好到优异的产率制备多种杂二芳基化合物，并且对于杂芳基氯化物以及受阻芳基和杂芳基卤化物的偶联显示出高水平的活性。还研究了控制某些杂环基序转化效率的特定因素。

  DOI：

  10.1021/ja068577p

文献信息

• Mild and General Conditions for Negishi Cross-Coupling Enabled by the Use of Palladacycle Precatalysts
  作者：Yang Yang、Nathan J. Oldenhuis、Stephen L. Buchwald

  DOI：10.1002/anie.201207750

  日期：2013.1.7

  A wide range of biaryls were synthesized by palladium‐catalyzed Negishi cross‐couplings at ambient temperature or with low catalyst loading. This protocol features the use of a recently reported aminobiphenyl palladacycle precatalyst to generate the catalytically active XPhosPd0 species. Significantly, a wide range of challenging heterocyclic and polyfluorinated aromatic substrates can be employed

  在环境温度或低催化剂负载量下，通过钯催化的根岸交叉偶联合成了多种联芳基化合物。该协议的特点是使用最近报道的氨基联苯钯环预催化剂来生成具有催化活性的 XPhosPd 0物质。值得注意的是，可以采用各种具有挑战性的杂环和多氟化芳香族底物来获得高产率的产品。
• 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY
  申请人：Yonezawa Shuji

  公开号：US20110237576A1

  公开（公告）日：2011-09-29

  The present invention provides a compound which has an effect of inhibiting amyloid-β production and is useful as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-β proteins. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein A is optionally substituted carbocyclic diyl or optionally substituted heterocyclic diyl; B is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R 1 is a group such as optionally substituted lower alkyl; R 2 is a group such as hydrogen; and R 3a and R 3b are each independently a group such as hydrogen, provided that the following compound is excluded.